Introduction
Recent years have seen the development of a number of approaches utilizing additive manufacturing techniques such as selective laser sintering [1, 2] , stereolithography [3] [4] [5] , fused filament fabrication [6] [7] [8] and 3D printing [9] [10] [11] [12] for the production of custom, defect-matched constructs for bone repair. These approaches require the ceramic and polymeric materials which are used with them to be processed by the application of high temperatures [2, 6-8, 10, 11] , ultraviolet light [3] [4] [5] or organic solvents [9, 12] . Whilst these harsh processing conditions cause little concern for the production of acellular scaffolds they have prevented the incorporation of cells and therapeutic biomolecules during the fabrication process. Post-fabrication addition of proteins and cells is often associated with the inability to provide long-term delivery and uneven seeding respectively. More importantly, it prevents these elements from being patterned within constructs to create functional heterogeneity. It is therefore important to develop production processes which are compatible with the inclusion of cells and biomolecules.
Bioprinting may provide a solution to this problem since it allows the fabrication of tissue engineered constructs at ambient conditions. To date this approach has predominantly been used to produce hydrogel constructs since these are typically the only class of materials which can be processed under such mild conditions [13] [14] [15] [16] [17] [18] [19] [20] . However there are issues with the use of hydrogel materials in orthopaedic applications including the very large disparity between their mechanical properties and those of bone [14, 15, 19, 20] . In addition to the inability of such weak materials to endure relevant in vivo loads, the low stiffness of hydrogels may inhibit the osteogenic differentiation of both endogenous and exogenous stem cells [21] .
A thermoresponsive microparticulate material based on a blend of poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) may overcome these issues. When mixed with aqueous carrier fluids at room temperature, these PLGA-based microparticles form extrudable pastes which can be formed to the desired scaffold shape. Incubation of these pastes at 37°C and surrounded by aqueous fluid leads to thermoresponsive liquid sintering and the formation of porous solid constructs [22] [23] [24] [25] [26] [27] . These constructs can be engineered with mechanical properties which are comparable to those of human cancellous bone [22] [23] [24] [25] [28] [29] [30] [31] . Previous studies utilizing this material have shown that proteins [24, 26, 27] and cells [22, 24] can tolerate the mixing and extrusion processes whilst maintaining activity and viability respectively. Encapsulated proteins can be delivered over several weeks [27] and the microporosity which is inherent to these constructs may also have beneficial effects on tissue ingrowth and angiogenesis in vivo.
The primary purpose in developing this material was to formulate an injectable bone defect filler but we postulated that its ability to be delivered by injection would also make it highly suitable for use with extrusion based additive manufacturing techniques. Presented here is the first assessment of the feasibility of using the Fab@Home bioprinting platform [14, 17, 18, 32] in conjunction with PLGA-based microparticle pastes to fabricate bone tissue engineering constructs at ambient conditions. Particular emphasis is placed on achieving the incorporation of viable cells and active proteins into the bioprinting process to produce living constructs which have appropriate mechanical properties for implantation into bone defects.
Materials and methods
2.1. Production and sintering of PLGA/PEG blend microparticles PLGA (85:15 lactide:glycolide, 53 kDa, Evonik Biomaterials, Birmingham, AL, USA) was melt blended at 90°C with poly(ethylene glycol) (PEG) (400 Da, Clariant, Leeds, UK) in a 93.5:6.5 (w:w) ratio. This melt blend was then milled in a Krups F203 mill which had been pre-cooled with liquid nitrogen. The resulting powder was manually sieved using analytical test sieves (Retsch (UK), Castleford, UK) to select the 50-100 μm size fraction.
To produce constructs these PLGA-PEG microparticles were suspended in aqueous carrier fluids to form dense pastes which were dispensed via bioprinting and then sintered by incubation in a humidified environment at 37°C for two hours, followed by submersion in 0.9% (w/v) sodium chloride in the same environment for a further 22 h.
PLGA-based microsphere manufacture
PLGA-PEG-PLGA triblock copolymer ('Triblock') was fabricated by a previously-published protocol [33] . Gel permeation chromatography measurements of the synthesized triblock copolymer using a PL-GPC 120 (Polymer Labs) indicated a molecular weight of 4590 Da and a polydispersity index of 1.60.
PLGA and Triblock were dissolved in dichloromethane at 14 and 6% (w/v) respectively to a total polymer mass of 1 g. A small amount of water (2% (v/ v) relative to the organic phase) was added to the polymer solution and this combination was homogenized for two minutes to form a primary emulsion using a Silverson L5M homogenizer (Silverson Machines, Chesham, UK) at 4000 rpm. The primary emulsion was then added to an aqueous solution of 0.3% (w/v) poly(vinyl alcohol) (PVA, 87-89% hydrolysed, 13-23 kDa, Sigma-Aldrich) and homogenized for two minutes at 2000 rpm to form a secondary emulsion. The secondary emulsion was stirred for 4 h and the hardened microspheres collected under vacuum filtration (0.2 μm filter mesh), snap frozen in liquid nitrogen and lyophilized for 48 h. Lysozyme was incorporated into microspheres by dissolution in the water used to form the primary emulsion (9 mg human serum albumin carrier protein (SigmaAldrich) and 1 mg lysozyme from chicken egg white (Sigma-Aldrich)). Primary emulsion production was carried out in 30 mL poly(tetrafluoroethylene) (PTFE) beakers (VWR International, Lutterworth, UK) and secondary emulsion in a 250 mL borosilicate glass beaker (Fisher Scientific) using 200 mL of PVA solution.
Immortalized human mesenchymal stem cells (ihMSCs)
Primary human mesenchymal stem cells (bone marrow-derived, TCS Cellworks, Buckingham, UK) were immortalized (ihMSCs) using a previously published protocol [34] . ihMSCs were cultured in Dulbecco's modified Eagle medium (Life Technologies, Paisley, UK) supplemented with 10% (v/v) foetal bovine serum (Sigma-Aldrich, Poole, UK), 1% (v/v) L-glutamine (Sigma-Aldrich), 1% (v/v) penicillin /streptomycin (Life Technologies) and 1% (v/v) nonessential amino acids (Sigma-Aldrich). Cultures were maintained at 37°C and 5% (v/v) CO 2 as monolayers on tissue culture treated polystyrene. At 80% confluency cells were passaged by trypsinization and reseeded between 1/5th and 1/8th of pre-passage density.
Bioprinting of PLGA-PEG microparticle pastes
The Fab@Home platform (Model 2) [35] was used in conjunction with 16 G tapered dispense tips (Adhesive Dispensing, Milton Keynes, UK) for microparticulate construct fabrication. To prevent early sintering of microparticles all materials were pre-cooled to 4°C and wherever possible sample preparation was carried out at this temperature as well. PLGA-PEG microparticles with or without a proportion of PLGA-based microspheres were mixed with aqueous carrier solutions containing one of the following viscosity modifiers-medium viscosity carboxymethyl cellulose (CMC) (catalogue number 12M8P, Ashland Speciality Ingredients, Poole, UK), high viscosity CMC (catalogue number 12M31P, Ashland) or Pluronic ® F-127 (Sigma-Aldrich). The concentrations of these modifiers were in the range 0.1-4% (w/v) and the solutions were mixed with the solid components at various v-w ratios in the range 1:1-1.7:1. The resulting pastes were loaded into syringe barrels for deposition using a material flow rate of 38.8 μL s
For the accuracy of unconfined compression testing it was important that bioprinted constructs had identical shapes and sizes and that they could be tested without the need for them to be trimmed. In order to achieve this PLGA-based microparticulate pastes were extruded into PTFE cylindrical moulds 6 mm in diameter and 12 mm in height. The current printing resolution is insufficient for producing such compression testing samples with precise shape and uniformity.
In order to incorporate cells into bioprinted pastes, suspensions of ihMSCs in PBS were first manually mixed by stirring with acellular solutions of high viscosity CMC to a final CMC concentration of 2% (w/v) and a final cell density of 2 × 10 6 mL −1
. The resulting cell suspensions were then combined with microparticles in a 1.4:1 (v:w) ratio for bioprinting.
Unconfined compression testing
Three sintered constructs per condition were subjected to unconfined compression testing using a TA. HDplus texture analyser (Stable Micro Systems, Godalming, UK). Samples were tested at 37°C immediately at the end of 24 h sintering. The probe movement rate was 0.04 mm s −1 (which equates to a 0.333% s
strain rate) and the test was continued to 50% strain.
2.6. Scanning electron microscopy and microcomputed tomography SEM was performed using a JSM 6060LV (JEOL, Welwyn Garden City, UK). Images were taken at a minimum of three different magnifications and in three different quadrants of each sample and three samples were imaged per condition. Micro-computed tomography (μCT) imaging was undertaken using a Skyscan 1174 (Bruker microCT, Kontich, Belgium). This analysis was performed on three samples per condition. Images were taken at 6.7 μm resolution every 0.4°of rotation from 0º to 180º and at each rotation step a total of 6 frames were averaged to produce the final image. The NRecon software provided by the manufacturer was used to reconstruct cross-sectional slices with ring artefact reduction set to 20, beam hardening to 20% and consistent thresholding across all samples. Finally CTAn was used to produce three-dimensional models of scanned samples and to perform analyses such as measurements of total porosity and pore size distribution. As with reconstruction in NRecon, consistent thresholding was applied across all samples to be compared and despeckling was also performed to remove objects of 100 voxels or less from reconstructed images prior to analysis and modelling.
Measurement of protein release rate from microspheres
To produce constructs for assessment of post-bioprinting lysozyme release rate and activity microparticle/microsphere mixtures were formulated into pastes using 2% (w/v) high viscosity CMC at a 1.4:1 (v:w) ratio. Pastes containing 400 mg of solid were then extruded into PTFE moulds and sintered for two hours prior to submersion in 3 mL of pre-warmed (37°C) PBS in 15 mL centrifuge tubes to initiate protein release. This study was conducted in triplicate and compared constructs containing lysozyme-loaded microspheres with those containing blank microspheres. Incubation was continued at 37°C for a period of 15 days under gentle agitation and at regular intervals the PBS was completely aspirated, assayed for total protein content and lysozyme activity and replaced. The Micro BCA Protein Assay Kit (Fisher Scientific) was used to quantify the total protein content of aspirated release medium. As per manufacturer's instructions 150 μL of each sample or standard was mixed in a 96-well plate well in triplicate with 150 μL of complete working reagent. After 2 h incubation at 37°C, the absorbance of the mixture in each well was measured at 562 nm.
The ability of lysozyme to lyse Micrococcus lysodeikticus bacteria was used to measure protein activity in release medium, which was compared to the total lysozyme released as calculated from BCA assay results. In triplicate in the wells of a 96-well plate 150 μL of each standard or sample was mixed with 100 μL of 2.3 mg mL −1 M. lysodeikticus suspension (Sigma-Aldrich). The drop in absorbance due to cell lysis over a three minute period was then read at 450 nm at 37°C.
Viability assessment of cells in PLGA-PEG pastes
Pre-bioprinting ihMSC counting and viability assessment were performed using an improved Neubauer haemocytometer and trypan blue (Fisher Scientific, Loughborough, UK) dye exclusion. The extruded material was incubated at 37°C in humidified environment for 30 min to allow the particles to fuse before immersion in culture medium. For each time point, three samples were made. For imaging cells, the extruded constructs were disassembled manually to expose the cells and then submerged in a 2 μM/4 μM calcein AM/ethidium homodimer-1 (live/dead) solution (Life Technologies) and incubated for 45 min. Samples were imaged using a Leica DM IRB inverted microscope (Leica Microsystems (UK), Milton Keynes, UK). Six fields of view were imaged for each of three samples to assess cell viability.
Statistical analysis
The homogeneity of variances across experimental groups was determined by Levene's test. Appropriate post hoc procedures were used after one way ANOVA for pairwise comparison of experimental groups. In cases of equal variance Tukey's procedure was applied, whilst the Games-Howell procedure was used for cases of unequal variance. All statistical tests were performed at the 5% significance level. For comparing cell viability, two-way ANOVA and Tukey's test were used with a α level of 0.05.
Results and discussion
3.1. Feasibility of bioprinting PLGA-based microparticulate pastes The PLGA-based microparticulates used in this work must be suspended in the carrier liquid at high densities to generate large numbers of bridging contacts and consequently sufficient mechanical strength. Meanwhile, the mixture of microparticulates and liquid carrier needs to be extruded with consistent composition using the Fab@Home model 2 bioprinting platform. We demonstrated that it was feasible to deposit the mixture using bioprinting by selecting the appropriate microparticle size, solid to carrier ratio and carrier concentration. Extruded microparticulate material could be sintered in PBS by a thermoresponsive sintering mechanism in which the glass transition temperature rose due to the leaching of the PEG compoonent. The size and shape of the bioprinted constructs were maintained after sintering, and sufficient mechanical integrity was acquired to allow handling and manipulation ( figure 1) . In order to allow consistent and controlled extrusion, the microparticulate pastes used in this study differed in several ways from those used in previous studies [22] [23] [24] [25] [26] [27] . To prevent syringe tips from becoming clogged smaller microparticles were used than in previous studies, with the 50-100 μm size fraction isolated in place of the 100-200 μm fraction. In addition, to prevent syneresis (preferential ejection of the fluid component), a greater proportion of carrier fluid was used (carrier to solid ratio of 1.4:1 as opposed to 0.6:1-1:1) and the concentration of medium viscosity CMC in the fluid was also increased (3% (w/v) as opposed to 0.5% (w/v)). Avoiding clogging and achieving 'complete extrusion' of the entire paste volume was considered a pre-requisite for ensuring that paste composition and thus ultimate mechanical properties remained consistent throughout fabrication.
Optimizing the mechanical properties of bioprinted constructs
The next stage in the development of this bioprintingbased approach to fabricate constructs was to optimize the process with respect to mechanical properties. To achieve this aim, alternative viscosity modifiers were considered alongside the medium viscosity CMC used up to this point. The minimum carrier to solid (v:w) ratios that permitted complete extrusion of microparticle pastes without syringe tip clogging are shown in table 1. Pluronic ® F127 was investigated alongside CMC as having potential to directly lubricate microparticle-microparticle interactions. It was found that as well as requiring larger ratios than the best concentrations of CMC to achieve complete extrusion (table 1) , all concentrations of Pluronic ® F127 produced pastes which displayed liquid-like behaviour after deposition and did not allow structures or patterns to be maintained through the sintering process.
It can be reasonably expected that a larger proportion of carrier leads to less microparticle-to-microparticle contacts and thus lower mechanical strength. The conditions which allowed the least liquid carrier to be used to achieve consistent extrusion without the syringe tips becoming clogged were considered optimal and were carried forward for further evaluation. On the basis of the results shown in table 1 the three most promising carriers were 3% (w/v) medium viscosity CMC, 2% (w/v) high viscosity CMC and 3% (w/ v) high viscosity CMC.
The mechanical properties of constructs produced using the chosen combinations were then assessed using unconfined compression testing, both at the derived minimum ratios of carrier to solid and at ratios either side. Close rations at either side of the minimum ratios were selected because tip clogging was sensitive to small changes in the carrier/solid ratio. The additional ratios were intended to indicate in principle whether any additional mechanical strength could be obtained by intentionally making the pastes 'too wet' or 'too dry'. On the basis of the yield stresses (figure 2) and Young's moduli (figure 3) of bioprinted constructs, 2 and 3% (w/v) high viscosity CMC (both at minimum ratios) appeared to be the most promising carriers for construct fabrication. These constructs had yield stresses of 1.22 and 1.15 MPa and Young's moduli of 54.4 and 57.3 MPa respectively. These values are lower than those obtained in other bone tissue engineering studies with harsher fabrication processes [1-4, 8, 10-12] but are nonetheless within the normal ranges for cancellous bone [28-31, 36, 37] .
In general, constructs dispensed with high viscosity carriers showed higher mechanical properties than those produced with the medium viscosity carrier. In a construct produced using medium viscosity CMC there is likely to be a more heterogeneous distribution of microparticles, creating 'strong points' and 'weak points' within the structure. The mechanical behaviour of the constructs will then result from the properties of the weak points more than the strong and the constructs as a whole will be less strong and yield more readily. This effect will be lessened in constructs produced using the high viscosity carriers as these are more effective at preventing syneresis and ensuring homogeneous distributions of microparticles.
Compression testing showed no significant differences between constructs produced using the same carrier with different carrier to solid ratios and so subsequent analysis was performed only on the central ratios. μCT and SEM imaging were used to measure and visualize the pore structures of constructs produced using the different carrier solutions. Constructs produced using 2 and 3% (w/v) high viscosity CMC had relatively low porosities of 10.8% and 12.4% respectively (figure 4) and these values are reflected in the relatively dense structures seen via SEM imaging (figure 5). Constructs produced using medium viscosity CMC as a carrier showed porosities which were not statistically different to those of other constructs. However the variability seen with this carrier was much higher than with others. This again suggested the inability of medium viscosity CMC to prevent syneresis, which resulted in large variations in porosity between different constructs.
The mean pore sizes for constructs produced using 2 and 3% (w/v) high viscosity CMC carriers were 65.3 and 76.6 μm (figure 6). It was found that constructs produced using 2% (w/v) high viscosity CMC had statistically smaller mean pore sizes than those produced with other carriers. This may suggest that this carrier is the most effective at ensuring homogenous microparticle distribution. It has been suggested that an optimal construct for bone regeneration needs to contain a large population of pores of around 200-400 μm in size in order to maximize tissue ingrowth [38] [39] [40] [41] . The pores produced here were mostly smaller than this suggested range but many were large enough to allow cell motion and proliferation in the constructs, based on the results of previous studies in bone tissue engineering [42, 43] . Additionally with appropriate development and optimization it may be possible to create pores in this desired size range by designing them into the bioprinted construct architecture. Table 1 . Minimum v-w ratios of a variety of aqueous carriers to solid required to produce PLGA-PEG microparticle pastes which could be extruded in their entirety by Fab@Home Model 2 bioprinting platform. Failure to achieve 'complete extrusion' indicates syneresis, tip clogging and inconsistent paste composition. 
Incorporation of cells and proteins in bioprinted constructs
Besides achieving mechanical properties that match with bone, incorporating biological factors such as cells and growth factors in the scaffold can potentially accelerate healing of complex bone defects. The ability to print the PLGA-PEG material at ambient temperature enables the incorporation of temperature-sensitive components such as cells and proteins in a spatially defined manner. The differentiation of MSCs in moulded scaffolds made of PLGA-PEG and PLGA particles has been studied previously [44] . As an initial study, here we investigated the bioactivity and viability of homogeneously incorporated proteins and cells. We first investigated the incorporation of therapeutic proteins. Using an approach utilized extensively by our group [33, 45] and others [5, [46] [47] [48] [49] lysozyme was incorporated into PLGA-based microspheres by a water-in-oil-in-water double emulsion technique. A PLGA-PEG-PLGA triblock copolymer [33] was used to modify the protein release profile. Lysozyme was being used here as a model protein for bone morphogenetic protein-2, which is a potent growth factor involved in bone development and repair [50] [51] [52] [53] . Lysozyme was chosen on the basis of the two proteins' similar molecular weights and isoelectric points. These protein-loaded microspheres were then incorporated into microparticle pastes used for bioprinting, with previous work suggesting a 3:1 (w:w) ratio of microparticles to microspheres as a suitable starting point [44] . A release study was undertaken to assess the controlled release of active protein from microspheres which had been incorporated into microparticulate pastes for bioprinting. In this study constructs containing lysozyme-loaded microspheres were found to be capable of delivering active protein for a period of at least 9 days (figure 7). The protein released by the microspheres was predominantly active (⩾61%), with no clear drop in activity observed across this period. Beyond the ninth day after the start of the study the total activity of released protein dropped below the sensitivity of the Micrococcus assay, but protein release could be observed by micro BCA assay up to the fifteenth day (supplementary figure 2) . This suggests that optimization of the microsphere formulation would allow active protein to be delivered over significantly longer periods as in previous studies [45] .
The incorporation of non-sintering microspheres as described above can potentially lower the mechanical properties of PLGA-PEG microparticulate constructs by reducing the number of bridging contacts between the thermoresponsive microparticles. This effect needs to be addressed in future studies aimed at further optimizing the construct production process. However, the reduction in mechanical strength may be lessened by reducing the proportion of microspheres in the constructs. Previous studies showed that the amount of protein encapsulated in a given mass of microspheres could be varied over approximately an order of magnitude whilst maintaining good encapsulation efficiency [33, 45, 54] . Increasing the ratio of protein to polymer would allow fewer microspheres to be incorporated whilst maintaining the total protein load per construct, and this would allow better retention of mechanical properties.
A further key step in the process development undertaken here was the incorporation of live cells in the production process. Cells were mixed manually using a plastic spatula into the microparticulate pastes and the effects of factors such as the cell density were not investigated at this stage. The viability of cells was found to be dependent on the carrier to solid ratio (figure 8). The cell viabilities for the 1.5:1 ratio were 87% and 77% at day 0 and day 1, respectively. Decreased cell viabilities were found for a higher ratio (1.4:1) at both time points. The viability for the 1.4:1 ratio dropped below 50% at day 1. This demonstrated that a small change in carrier:particle ratio could have Figure 6 . Mean pore sizes of bioprinted PLGA-PEG microparticulate scaffolds as assessed by μCT imaging and analysis (n = 3). PLGA-PEG microparticles were suspended in a variety of aqueous carriers at different carrier to solid (v:w) ratios for bioprinting into cylindrical PTFE moulds. Samples were tested after 24 h sintering. Error bars show one standard deviation and statistically-significant (p < 0.05) differences are denoted by (*). Figure 7 . Lysozyme release from PLGA microspheres encapsulated within bioprinted PLGA-PEG microparticulate constructs. A 9:1 (w:w) mixture of HSA and lysozyme was encapsulated in PLGA microspheres via a double emulsion protocol with a total protein content of 1% (w/w) relative to polymer. Expected activity levels are one tenth of total protein level measured by Micro BCA assay. Error bars represent one standard deviation. a significant effect on cell viability. The yield stress and Young's modulus for the 1.5:1 ratio material was lower than those of 1.4:1 but not statistically significant. We think that the significant drop in cell viability could be due to reduced lubrication resulted from a smaller amount of viscous carrier. A small reduction in lubrication could significantly increase the mechanical stress on cells during extrusion though a needle.
Conclusions
The work presented here has demonstrated the essential feasibility of using bioprinting and a thermoresponsive material to produce constructs which have mechanical properties comparable to cancellous bone. The mild conditions used for bioprinting and material sintering have allowed viable cells and active therapeutic proteins to be incorporated into the construct production process. The approach adopted in this study has the potential for patterning biological constituents within constructs to achieve more sophisticated architectures, which circumvents the problems associated with post-fabrication cell seeding and biomolecule addition. The complexity of the final printed scaffold will depend on individual applications in which the scaffold is intended to be used.
